Ours Privacy raises $15 million Series A backed by LightBank and Health Velocity Capital
Ours PrivacyCompany
LightbankInvestor
Health Velocity CapitalInvestor
Ours Privacy announced a $15 million Series A on Sept. 10, 2026, led by LightBank and Health Velocity Capital, to fund the expansion of its HIPAA‑safe customer data platform for healthcare marketers.
Ours Privacy secured a $15 million Series A on Sept. 10, 2026, with LightBank and Health Velocity Capital as the sole investors, marking a clear infusion of growth capital for the HIPAA‑compliant CDP provider. The round, disclosed in a podcast interview with co‑founder Jessica Holton, will be used to scale the company’s privacy‑first data infrastructure and accelerate AI‑driven marketing solutions for the health‑tech sector.
Deal Terms
The Series A round was not accompanied by a disclosed valuation or revenue multiple, and the investors did not announce any board seats. LightBank and Health Velocity Capital, both active in health‑tech and fintech, are the exclusive backers, signaling confidence in Ours Privacy’s approach to marrying compliance with performance marketing. The capital will fund product development, go‑to‑market expansion, and deeper integration of consent‑management tools across web and mobile channels.
Market Context
Healthcare marketers face a regulatory paradox: stringent HIPAA and state privacy laws on one side, and the need for granular performance data on the other. Ours Privacy’s platform strips personally identifiable health information while preserving the analytics needed for campaign optimization, a model that aligns with evolving HHS and OCR guidance. The company already serves more than 200 health organizations, ranging from digital‑health startups to multibillion‑dollar health systems, and positions itself as a bridge between compliance and growth.
The Series A arrives as AI becomes embedded in marketing stacks, raising the stakes for clean, consent‑driven data. By building a privacy‑first architecture, Ours Privacy claims to unlock richer AI insights without exposing protected health information, a proposition that could set a new standard for health‑tech SaaS vendors.
The funding round underscores a broader investor appetite for niche B2B SaaS solutions that solve regulatory friction points. As health‑tech firms scale, the demand for compliant data pipelines is expected to outpace traditional analytics tools, creating a tailwind for platforms that can certify HIPAA safety while delivering actionable marketing intelligence.
Why It Matters
The infusion of $15 million gives Ours Privacy the runway to deepen its product roadmap, particularly around AI‑enabled segmentation and cross‑channel attribution. For existing customers, the capital should translate into faster feature releases and tighter integrations with ad‑tech partners, reducing the operational overhead of managing consent and data de‑identification. Competitors that rely on generic analytics stacks may find themselves at a disadvantage as health brands prioritize vendors that can demonstrably protect patient data while delivering measurable ROI.
For LightBank and Health Velocity Capital, the investment expands their exposure to a high‑growth niche where compliance is a barrier to entry. Their backing may also accelerate partnership opportunities with larger health systems that are increasingly scrutinized for data‑privacy practices, potentially shifting market share away from legacy data platforms that lack built‑in HIPAA safeguards.
Key Points
- Ours Privacy raised $15 million in a Series A led by LightBank and Health Velocity Capital
- The round will fund scaling of the company’s HIPAA‑safe CDP and AI‑driven marketing tools
- Ours Privacy currently serves over 200 healthcare organizations across the provider spectrum
- Investors did not disclose valuation or revenue multiples for the deal
- The funding targets deeper consent‑management capabilities and cross‑channel measurement
Analysis
The $15 million Series A positions Ours Privacy at the intersection of compliance and performance, a space where valuation multiples are still emerging. While the round’s valuation was undisclosed, comparable HIPAA‑compliant SaaS firms have traded at 8‑12 x ARR, suggesting Ours Privacy could be valued in the low‑double‑digit millions if its ARR approaches the $10‑15 million range. The capital infusion arrives as AI becomes a core differentiator in marketing tech, and a privacy‑first data foundation is increasingly viewed as a prerequisite for reliable AI models. For operators, the deal highlights the importance of embedding consent and de‑identification early in the data stack to avoid costly retrofits. Investors see a clear upside: health‑tech spend on SaaS tools is projected to grow at a 20% CAGR, and platforms that can certify HIPAA compliance while delivering actionable insights are likely to command premium multiples. Ours Privacy’s ability to scale its AI capabilities on top of a compliant data layer could set a template for future health‑tech SaaS investments, prompting more capital to flow into niche compliance‑focused verticals.